目的 观察重组人白细胞介素-11(rhIL-11)对急性白血病(AL)化疗后血小板(Plt)减少的疗效.方法 对42例AL(治疗组)化疗后Pit＜20×109/L的患者皮下注射rhIL-111.5 mg/d,用至Plt≥40×109/L停药;对其中17例初诊急性髓系白血病(AML)完成2个疗程化疗后统计疗效,并以35例未加用rhIL-11的AL患者和其中15例初诊AML(对照组)完成2个疗程化疗患者作对照.结果 治疗组Plt升到≥40×109/L所需时间平均为(9.8±2.7)d,短于对照组(14.6±4.8)d(P＜0.05);治疗组在第2个疗程化疗后Ph＜15×109/L的患者有3例(17.6%),明显少于对照组10例(66.7%)(P＜0.05);第2个疗程化疗前Plt水平和化疗后Plt最低平均水平,治疗组为(173.7±81.2)×109/L和(23,5±18.3)X 109/L高于对照组(99.6±74.5)×109/L和(10.2±9.8)×109/L(P＜0.05);治疗组和对照组的完全缓解(CR)率分别是70.6%和73.3%,有效(CR+PR)率分别是82.4%和86.7%,二组比较差异无统计学意义(P＞0.05).结论 rhIL-11可安全有效地促进AL化疗后Plt恢复,而且疗效持久.%Objective To investigate the treatment of recombinant human interleukin-11(rhIL-11)to chemotherapy-induced thrombocytopenia in acute leukemia(AL).Methods 42 AL patients whose platelet count dropped below 20×109/L after chemotherapy received rhIL-11 by 1.5 mg daily until the platelet count was increased above 40×109/L.The efficiency of chemotherapy to 17 newly diagnosed acute myelocytic leukemia(AML)patients was evaluated after receiving two periods of chemotherapy.35 AL patients and 15 newly diagnosed AML patients were used as controls.Results The mean time of platelet count increasing from 20×109/L to above 40×109/L Was shorter in treating group (9.8±2.7)d than in control group(14.6±4.8)d .The number of patients whose platelet＜15×109/L was less in treating group than in control group after second chemotherapy,and the minimum mean count of platelet Was higher in treating group(23.5±18.3)×109/L than that in control group(10.2±9.8)×109/L .CR and CR+PR rate were not different between treating group and control group. Conclusion rhlL-11 can safely and effectively promote chemotherapy-induced platelet recovery in patients of acute leukemia with persistent affection.
展开▼
